Literature DB >> 16101513

Altering the tropism of lentiviral vectors through pseudotyping.

James Cronin1, Xian-Yang Zhang, Jakob Reiser.   

Abstract

The host range of retroviral vectors including lentiviral vectors can be expanded or altered by a process known as pseudotyping. Pseudotyped lentiviral vectors consist of vector particles bearing glycoproteins (GPs) derived from other enveloped viruses. Such particles possess the tropism of the virus from which the GP was derived. For example, to exploit the natural neural tropism of rabies virus, vectors designed to target the central nervous system have been pseudotyped using rabies virus-derived GPs. Among the first and still most widely used GPs for pseudotyping lentiviral vectors is the vesicular stomatitis virus GP (VSV-G), due to the very broad tropism and stability of the resulting pseudotypes. Pseudotypes involving VSV-G have become effectively the standard for evaluating the efficiency of other pseudotypes. This review samples a few of the more prominent examples from the ever-expanding list of published lentiviral pseudotypes, noting comparisons made with pseudotypes involving VSV-G in terms of titer, viral particle stability, toxicity, and host-cell specificity. Particular attention is paid to publications of successfully targeting a specific organ or cell types.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16101513      PMCID: PMC1368960          DOI: 10.2174/1566523054546224

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  102 in total

1.  Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes.

Authors:  Michael D Mühlebach; Isabel Schmitt; Stefanie Steidl; Jörn Stitz; Matthias Schweizer; Thomas Blankenstein; Klaus Cichutek; Wolfgang Uckert
Journal:  J Mol Med (Berl)       Date:  2003-10-24       Impact factor: 4.599

2.  Lentivirus vector purification using anion exchange HPLC leads to improved gene transfer.

Authors:  Kaoru Yamada; Douglas M McCarty; Victoria J Madden; Christopher E Walsh
Journal:  Biotechniques       Date:  2003-05       Impact factor: 1.993

3.  Continuous high-titer HIV-1 vector production.

Authors:  Yasuhiro Ikeda; Yasuhiro Takeuchi; Francisco Martin; Francois-Loic Cosset; Kyriacos Mitrophanous; Mary Collins
Journal:  Nat Biotechnol       Date:  2003-04-07       Impact factor: 54.908

4.  Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung.

Authors:  Maria Fe Medina; Gary P Kobinger; John Rux; Mehdi Gasmi; David J Looney; Paul Bates; James M Wilson
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

5.  Lentiviral vectors pseudotyped with baculovirus gp64 efficiently transduce mouse cells in vivo and show tropism restriction against hematopoietic cell types in vitro.

Authors:  C A Schauber; M J Tuerk; C D Pacheco; P A Escarpe; G Veres
Journal:  Gene Ther       Date:  2004-02       Impact factor: 5.250

6.  Human immunodeficiency virus type 1-derived lentivirus vectors pseudotyped with envelope glycoproteins derived from Ross River virus and Semliki Forest virus.

Authors:  Christoph A Kahl; Jon Marsh; Joanne Fyffe; David A Sanders; Kenneth Cornetta
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

7.  Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modified RD114 envelope glycoproteins.

Authors:  Xian-Yang Zhang; Vincent F La Russa; Jakob Reiser
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

8.  Correction of bleeding diathesis without liver toxicity using arenaviral-pseudotyped HIV-1-based vectors in hemophilia A mice.

Authors:  Frank Park
Journal:  Hum Gene Ther       Date:  2003-10-10       Impact factor: 5.695

9.  Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain.

Authors:  V Baekelandt; K Eggermont; M Michiels; B Nuttin; Z Debyser
Journal:  Gene Ther       Date:  2003-11       Impact factor: 5.250

10.  PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum.

Authors:  Maria A Croyle; Shellie M Callahan; Alberto Auricchio; Gregg Schumer; Klause D Linse; James M Wilson; Lane J Brunner; Gary P Kobinger
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

View more
  174 in total

1.  Endoplasmic reticulum chaperone gp96 is essential for infection with vesicular stomatitis virus.

Authors:  Stuart Bloor; Jonathan Maelfait; Rebekka Krumbach; Rudi Beyaert; Felix Randow
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

2.  Replication-competent lentivirus analysis of clinical grade vector products.

Authors:  Kenneth Cornetta; Jing Yao; Aparna Jasti; Sue Koop; Makhaila Douglas; David Hsu; Larry A Couture; Troy Hawkins; Lisa Duffy
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

Review 3.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

4.  Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.

Authors:  Guido Wollmann; Eugene Drokhlyansky; John N Davis; Connie Cepko; Anthony N van den Pol
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

5.  Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice.

Authors:  Carolina Gándara; Valerie Affleck; Elizabeth Ann Stoll
Journal:  Hum Gene Ther Methods       Date:  2018-01-24       Impact factor: 2.396

6.  Reevaluation of the requirement for TIP47 in human immunodeficiency virus type 1 envelope glycoprotein incorporation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Peter Y Mercredi; Sampson K Kyere; Justin Donlan; Tsutomu Murakami; Michael F Summers; Simon Cocklin; Eric O Freed
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

7.  Lower levels of gamma interferon expressed by a pseudotyped single-cycle simian immunodeficiency virus enhance immunogenicity in rats.

Authors:  Yue Peng; Fan-ching Lin; Paulo H Verardi; Leslie A Jones; Tilahun D Yilma
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

Review 8.  A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme.

Authors:  Thomas Wirth
Journal:  World J Exp Med       Date:  2011-12-20

9.  The ORF7b protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is expressed in virus-infected cells and incorporated into SARS-CoV particles.

Authors:  Scott R Schaecher; Jason M Mackenzie; Andrew Pekosz
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus.

Authors:  Danit Finkelshtein; Ariel Werman; Daniela Novick; Sara Barak; Menachem Rubinstein
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.